Target inhibition in antiangiogenic therapy a wide spectrum of selectivity and specificity

Cancer Journal

Volumn 16, Issue 6, 2010, Pages 635-642

  Kelly, Ronan J ^a   Darnell, Colleen ^b   Rixe, Olivier ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

on off target; selective; specific; Vascular endothelial growth factor

Indexed keywords

3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; 4 [BIS(2 CHLOROETHYL)OXIDOAMINO]PHENYLALANINE; AE 941; AFLIBERCEPT; ALACIZUMAB PEGOL; ANGIOGENESIS INHIBITOR; AXITINIB; BEVACIZUMAB; BRIVANIB; CILENGITIDE; DOCETAXEL; EZN 2968; IMC 18F1; MK 0752; MOTESANIB; OMBRABULIN; OMP 21M18; PAZOPANIB; RAMUCIRUMAB; SEMAXANIB; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VADIMEZAN; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VATALANIB;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER SURVIVAL; CARCINOGENESIS; CELL DIFFERENTIATION; DRUG EFFICACY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG TARGETING; ENDOTHELIUM CELL; GASTROINTESTINAL TOXICITY; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; METASTASIS; NEPHROTOXICITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STEM CELL NICHE; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78650506417     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3181ff37cf     Document Type: Review

References (71)

1. Ellis LM, Hicklin DJ. Pathways mediating resistance to vascular endo-thelial growth factor-targeted therapy. Clin Cancer Res. 2008;14: 6371-6375.
2. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002;20:4368-4380.
3. Takayama K, Ueno H, Nakanishi Y, et al. Suppression of tumor angio-genesis and growth by gene transfer of a soluble form of vascular endo-thelial growth factor receptor into a remote organ. Cancer Res. 2000;60: 2169-2177.
4. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irino-tecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
5. Ross JS, Schenkein DP, Pietrusko R, et al. Targeted therapies for cancer 2004. Am J Clin Pathol. 2004;122:598-609.
6. Woolard J, Bevan HS, Harper SJ, et al. Molecular diversity of VEGF-A as a regulator of its biological activity. Microcirculation. 2009;16: 572-592.
7. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25:581-611. (Pubitemid 39099316)
8. Hiratsuka S, Minowa O, Kuno J, et al. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA. 1998;95:9349-9354.
9. Milkiewicz M, Haas TL. Effect of mechanical stretch on HIF-1 and MMP-2 expression in capillaries isolated from overloaded skeletal muscles: laser capture microdissection study. Am J Physiol Heart Circ Physiol. 2005;289:H1315YH1320.
10. Maharaj AS, D'Amore PA. Roles for VEGF in the adult. Microvasc Res. 2007;74:100-113.
11. Coultas L, Chawengsaksophak K, Rossant J. Endothelial cells and VEGF in vascular development. Nature. 2005;438:937-945.
12. Maharaj AS, Saint-Geniez M, Maldonado AE, et al. Vascular endo-thelial growth factor localization in the adult. Am J Pathol. 2006;168: 639-648.
13. Monacci WT, Merrill MJ, Oldfield EH. Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues. Am J Physiol. 1993;264:C995-C1002.
14. Fong GH, Rossant J, Gertsenstein M, et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature. 1995;376:66-70.
15. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983-985.
16. Kilic Ü, Kilic E, Jarve A, et al. Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1/2 and Akt pathways. J Neurosci. 2006;26:12439-12446.
17. Li J, Hampton T, Morgan JP, et al. Stretch-induced VEGF expression in the heart. J Clin Invest. 1997;100:18-24.
18. Ellis LM. The role of neuropilins in cancer. Mol Cancer Ther. 2006;5: 1099-1107.
19. Pan Q, Chanthery Y, Liang WC, et al. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell. 2007;11:53-67.
20. Uchida N, Nagai K, Sakurada Y, et al. Distribution of VEGF and Flt-1 in the normal dog tissues. J Vet Med Sci. 2008;70:1273-1276.
21. Kaplan RN, Rafii S, Lyden D. Preparing the Bsoil[: the premetastatic niche. Cancer Res. 2006;66:11089-11093.
22. Lorusso PM, Eder JP. Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology. Expert Opin Investig Drugs. 2008;17: 1013-1028
23. Cascone T, Gridelli C, Ciardiello F. Combined targeted therapies in non-small cell lung cancer: a winner strategy? Curr Opin Oncol. 2007;19: 98-102.
24. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinYpaclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-957.
25. Presta LG. Engineering antibodies for therapy. Curr Pharm Biotechnol. 2002;3:237-256.
26. Krämer I, Lipp HP. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. J Clin Pharm Ther. 2007;32:1-14.
27. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8:579-591.
28. Ostendorf T, De Vriese AS, Floege J. Renal side effects of anti-VEGF therapy in man: a new test system. Nephrol Dial Transplant. 2007;22: 2778-2780.
29. Eremina V, Baelde HJ, Quaggin SE. Role of the VEGFYa signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular filtration barrier. Nephron Physiol. 2007;106: p32-p37.
30. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358:1129-1136.
31. Sela S, Itin A, Natanson-Yaron S, et al. A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ Res. 2008;102:1566-1574.
32. Zachary I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol. 2001; 280:C1375-C1386. (Pubitemid 32553192)
33. Sandler A, Gray R, Perry MC, et al. PaclitaxelYcarboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355: 2542-2550.
34. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25: 1539-1544.
35. Browder T, Butterfield CE, Kräling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60:1878-1886.
36. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58-62.
37. Rousseau S, Houle F, Kotanides H, et al. Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase. J Biol Chem. 2000;275:10661-10672.
38. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose Bchemo-switch[ regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol. 2005;23:939-952.
39. Bates DO, Cui TG, Doughty JM, et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 2002;62:4123-4131.
40. Woolard J, Wang WY, Bevan HS, et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 2004;64:7822-7835.
41. Bates DO, Harper SJ. Therapeutic potential of inhibitory VEGF splice variants. Future Oncol. 2005;1:467-473.
42. Nowak DG, Woolard J, Amin EM, et al. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J Cell Sci. 2008;121:3487-3495.
43. Varey AH, Rennel ES, QiuY,etal. VEGF165b,anantiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colo-rectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. Br J Cancer. 2008;98:1366-1379.
44. Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26:127-132.
45. Billemont B, Izzedine H, Rixe O. Macrocytosis due to treatment with sunitinib. N Engl J Med. 2007;357:1351-1352; author reply 1352.
46. Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol. 2007;8:975-984.
47. Drevs J, Konerding MA, Wolloscheck T, et al. The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma. Angiogenesis. 2004;7:347-354.
48. Ciardiello F, Caputo R, Damiano V, et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res. 2003;9: 1546-1556.
49. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endo-thelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002;62:4645-4655.
50. Herbst RS, Sun Y, Korfee S, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZODIAC). J Clin Oncol (Meeting Abstracts). 2009;27: CRA8003.
51. Lau SC, Rosa DD, JaysonG.Technology evaluation: VEGF Trap (cancer), Regeneron/Sanofi-Aventis. Curr Opin Mol Ther. 2005;7:493-501.
52. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA. 2002;99: 11393-11398.
53. IzzedineH,BrocheriouI,DerayG,et al. Thrombotic microangiopathy and anti-VEGF agents. Nephrol Dial Transplant. 2007;22:1481-1482.
54. Lockhart AC, Rothenberg ML, Dupont J, et al. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol. 2010;28:207-214.
55. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol. 2004;5:343-354.
56. Haase VH. Hypoxia-inducible factors in the kidney. Am J Physiol Renal Physiol. 2006;291:F271YF281.
57. Bernhardt WM, Schmitt R, Rosenberger C, et al. Expression of hypoxia-inducible transcription factors in developing human and rat kidneys. Kidney Int. 2006;69:114-122.
58. Greenberger LM, Horak ID, Filpula D, et al. A RNA antagonist of hypoxia-inducible factor-1>, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther. 2008;7:3598-3608.
59. Bray SJ. Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol. 2006;7:678-689.
60. Sainson RC, Harris AL. Regulation of angiogenesis by homotypic and heterotypic Notch signalling in endothelial cells and pericytes: from basic research to potential therapies. Angiogenesis. 2008;11:41-51.
61. Noguera-Troise I, Daly C, Papadopoulos NJ, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature. 2006;444:1032-1037.
62. Chan SM, Weng AP, Tibshirani R, et al. Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood. 2007;110:278-286.
63. Beverly LJ, Felsher DW, Capobianco AJ. Suppression of p53 by Notch in lymphomagenesis: implications for initiation and regression. Cancer Res. 2005;65:7159-7168.
64. Vilimas T, Mascarenhas J, Palomero T, et al. Targeting the NF-JB signaling pathway in Notch1-induced T-cell leukemia. Nat Med. 2007;13:70-77.
65. Pollak MR. Focal segmental glomerulosclerosis: recent advances. Curr Opin Nephrol Hypertens. 2008;17:138-142.
66. Kretzler M, Allred L. Notch inhibition reverses kidney failure. Nat Med. 2008;14:246-247.
67. Niranjan T, Bielesz B, Gruenwald A, et al. The Notch pathway in po-docytes plays a role in the development of glomerular disease. Nat Med. 2008;14:290-298.
68. Cheng HT, Kim M,Valerius MT, etal. Notch2, but not Notch1, is required for proximal fate acquisition in the mammalian nephron. Development. 2007;134:801-811.
69. Krop IE, Kosh M, Fearen I, et al. Phase I pharmacokinetic (PK), and pharmacodynamic (PD) trial of the novel oral Notch inhibitor MK-0752 in patients (pts) with advanced breast cancer (BC) and other solid tumors. J Clin Oncol (Meeting Abstracts). 2006;24: 10574.
70. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
71. Ruoslahti E. Vascular zip codes in angiogenesis and metastasis. Biochem Soc Trans. 2004;32:397-402.